ROS1

Diseases

• Lung cancer50 trials
• Childhood cancers14 trials
• Sarcoma5 trials
• Neuroblastoma4 trials
• Colorectal cancer3 trials
• Kidney cancer3 trials
• Thyroid cancer3 trials
• Melanoma2 trials
• Gastric and esophageal cancer1 trial
• Glioblastoma1 trial
• Liver and biliary tract cancer1 trial
• Multiple myeloma1 trial
• Neuroendocrine tumours1 trial
• Ovarian cancer1 trial
• Pancreatic cancer1 trial
• Triple-negative breast cancer1 trial

The last 24 months

New trials, publications, preprints and grants on this target, month by month.

TrialsPublicationsPreprintsGrants

• Trial

  Molecularly Stratified Trial for Newly Diagnosed Infant-Type Hemispheric Glioma

  1 Nov 2026· PHASE2 · NOT_YET_RECRUITING· CTGOV

• Trial

  Study of SIM0518 in Participants With ALK-Positive or ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  1 Nov 2026· PHASE1 · NOT_YET_RECRUITING· CTGOV

• Trial

  Repotrectinib Post-Marketing Surveillance in Korean Patients With ROS1-Positive Non-Small Cell Lung Cancer (NSCLC) or Solid Tumors Harboring a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion

  31 Oct 2026· NA · NOT_YET_RECRUITING· CTGOV

• Trial

  A Phase III Study to Evaluate the Efficacy and Safety of JYP0322 in Previously Untreated ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  30 Oct 2026· PHASE3 · NOT_YET_RECRUITING· CTGOV

• Publication

  Probable Stevens-Johnson Syndrome During Taletrectinib Treatment After Crizotinib-Related Rash in ROS1-Positive Lung Cancer.

  29 Oct 2026· Respirology case reports· PUBMED

• Publication

  Primary Lung Adenocarcinoma in a Pediatric Patient With ROS1 Rearrangement and Uncommon Paraneoplastic Features.

  28 Oct 2026· Pediatric blood & cancer· PUBMED

• Publication

  Detection of Actionable Genomic Alterations beyond EGFR, ALK and ROS1 in Non-Small Cell Lung Carcinoma: A Real-World Evaluation of a Pathology-Led Staggered Reflex Predictive Biomarker Testing Strategy in a Resource-Limited Setting.

  14 Oct 2026· Clinical lung cancer· PUBMED

• Publication

  Evaluating taletrectinib in the treatment of patients with ROS1 fusion-positive non-small cell lung cancer.

  8 Oct 2026· Future oncology (London, England)· PUBMED

• Publication

  Case report: successful use of repotrectinib in a ROS1 fusion-positive lung adenocarcinoma patient with severe renal insufficiency and prior tyrosine kinase inhibitor treatment failure.

  7 Oct 2026· Anti-cancer drugs· PUBMED

• Publication

  Type II ROS1 Inhibition Overcomes Type I Inhibitor Resistance in ROS1 Fusion-Positive Lung Cancers: A Phase II Trial of Cabozantinib.

  5 Oct 2026· Clinical cancer research : an official journal of the American Association for Cancer Research· PUBMED

• Publication

  Zidesamtinib in ROS1-positive NSCLC with brain metastases: clinical evidence and therapeutic implications.

  9 Sept 2026· Annals of medicine and surgery (2012)· PUBMED

• Trial

  Immunotherapy Without Chemotherapy for Advanced Lung Cancer Patients With High PD-L1 Levels

  21 Aug 2026· PHASE2 · RECRUITING· CTGOV

• Publication

  Zidesamtinib (Jideytro®): a new selective, brain-penetrant ROS1 inhibitor approved for the treatment of ROS1-positive non-small cell lung cancer.

  18 Aug 2026· Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents· PUBMED

• Publication

  Development of clinical-radiological prediction models to prioritize ALK, ROS1, and RET fusion testing in major driver alteration-negative non-small cell lung cancer.

  30 Jul 2026· Journal of thoracic disease· PUBMED

• Publication

  Comparative efficacy of taletrectinib versus first-generation TKIs in TKI-naïve ROS1+ non-small cell lung cancer: A matching-adjusted indirect comparison.

  18 Jul 2026· Lung cancer (Amsterdam, Netherlands)· PUBMED

• Publication

  EZR-ROS1-rearranged lung adenocarcinoma presenting as diffuse cystic lung disease mimicking lymphangioleiomyomatosis: a case report.

  14 Jul 2026· Translational lung cancer research· PUBMED

• Publication

  Intracranial Efficacy of Crizotinib and Postprogression Therapeutic Strategies in Advanced c-ros Oncogene 1 (ROS1)-Positive Non-Small Cell Lung Cancer (NSCLC), a Multicenter Real-World Study.

  13 Jul 2026· MedComm· PUBMED

• Publication

  Impact of Prior Systemic Chemotherapy on Response to ROS1 Tyrosine Kinase Inhibitors in ROS1-Rearranged Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.

  10 Jul 2026· JCO precision oncology· PUBMED

• Publication

  Analysis of the coding transcriptome in NSCLC highlights variant-specific gene expression and signaling in CD74-ROS1 fusions.

  27 Jun 2026· Scientific reports· PUBMED

• Publication

  In vitro and in silico modelling of ROS1-positive non-small cell lung cancer reveals fusion-dependent tyrosine kinase inhibitor responses.

  23 Jun 2026· Molecular oncology· PUBMED

• Publication

  ROS1-Mutated Inoperable Spindle Cell Sarcoma Treated With Repotrectinib-A Case Report.

  18 Jun 2026· JCO precision oncology· PUBMED

• Publication

  Real-world treatment sequencing and survival in ROS1-Rearranged NSCLC across evolving treatment eras: Findings from the AURORA multi-centre registry (AURORA-ROS1).

  17 Jun 2026· Lung cancer (Amsterdam, Netherlands)· PUBMED

• Publication

  Case Report: Dynamic TKI combination strategies for EGFR-mutant NSCLC with acquired ROS1 fusion and brain metastases.

  4 Jun 2026· Frontiers in oncology· PUBMED

• Publication

  Novel Pattern of Nuclear Staining With ROS1 Immunohistochemistry: A Case Report.

  2 Jun 2026· Case reports in pulmonology· PUBMED

• Publication

  Acquired ROS1 Intragenic Rearrangements as a Resistance Mechanism in EGFR-Mutant Non-Small Cell Lung Cancer: A Case Series.

  27 May 2026· Current oncology (Toronto, Ont.)· PUBMED

• Publication

  Prognostic value of ROS1 rearrangement in lung adenocarcinoma stratified by clinicopathologic and radiological features: a retrospective cohort study.

  26 May 2026· Translational lung cancer research· PUBMED

• Publication

  Novel germline genetic variants associated with venous thrombo-embolism (VTE) and arterial thrombo-embolism (ATE) risk in patients with ALK and ROS1 fusion non-small cell lung cancer (NSCLC).

  22 May 2026· Thrombosis research· PUBMED

• Publication

  [Clinicopathological Characteristics of ROS1-positive Non-small Cell Lung Cancer Based on Next-generation Sequencing].

  20 May 2026· Zhongguo fei ai za zhi = Chinese journal of lung cancer· PUBMED

• Publication

  Response to crizotinib treatment for ROS1 p.H1999N mutation and secondary EGFR p.V774M mutation after drug resistance: a Case Report.

  8 May 2026· Frontiers in pharmacology· PUBMED

• Publication

  Correction: Circular RNA F-circSR derived from SLC34A2-ROS1 fusion gene promotes cell migration in non-small cell lung cancer.

  2 May 2026· Molecular cancer· PUBMED

Who works on it

Researchers who published on this target. Leave out your own co-author circle to find people you do not know yet.

No published researcher profile on this target yet.